Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: Analysis of USRDS database

American Journal of Nephrology

Volumn 29, Issue 6, 2009, Pages 501-508

  Jindal, Rahul M ^a,b   Das, Neal P ^c   Neff, Robert T ^a   Hurst, Frank P ^a   Falta, Edward M ^a   Elster, Eric A ^a   Abbott, Kevin C ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^c TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

Antithymocyte globulin; Basiliximab; Daclizumab; End stage kidney disease; Graft loss; Induction; Interleukin 2 inhibitor; Kidney transplant; Medicare claim; Survival; United States Renal Data System

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN RECEPTOR; MYCOPHENOLIC ACID; RABBIT ANTISERUM; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DATA BASE; DEATH; ETHNIC DIFFERENCE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; ANIMALS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RABBITS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 57049125222     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000182816     Document Type: Article

References (16)

1. - 2006 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1996-2005. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
2. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D: Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-1977.
3. Bunnapradist S, Takemoto SK: Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc 2005;37:889-891.
4. Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G: Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56.
5. Mourad G, Rostaing L, Legendre C, Garrigue V, Ther vet E , Dura nd D: Sequentia l protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78: 584-590.
6. Haririan A, Morawski K, Sillix DH, et al: Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 2005;79:716-721.
7. Pallet N, Thervet E, Alberti C, et al: Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant 2005;5:2682-2687.
8. Patlolla V, Zhong X, Reed GW, Mandelbrot DA: Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007;7:1832-1842.
9. Becker SO, Ichino A: Estimation of average treatment effects based on propensity scores. Stata J 2002;2: 358-377.
10. Ciancio G, Burke GW, Suzart K, et al: The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am J Transplant 2003;3:1010-1016.
11. Ciancio G, Burke GW, Gaynor JJ, et al: A randomized trial of three renal transplant induction antibodies: early comparison of ta-crolimus, mycophenolate mofetil, and steroiddosing, and newer immune-monitoring. Transplantation 2005;80:457-465.
12. Ciancio G, Burke GW, Gaynor JJ, et al: A randomized trial of thymoglobulin vs. lemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008;22:200-210.
13. Stirnemann PM, Takemoto SK, Schnitzler MA, et al: Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J Am Soc Nephrol 20 06;1 7: 2299 -2306.
14. Hardinger KL, Bohl DL, Schnitzler MA, et al: A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005;80:41-46.
15. Knight RJ, Kerman RH, Schoenberg L, et al: The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004;78: 904-910.
16. Clesca P, Dirlando M, Park SI, et al: Thymoglobulin and rate of infectious complications after transplantation. Transplant Proc 2007;39:463-464.